Abstract

Central memory CD8+ T cells expressing the adhesion molecule CD62L (L-selectin) are potent mediators of anti-cancer immunity due to their ability to proliferate extensively upon antigen re-stimulation. The interaction of selectin with its ligands mediates leukocyte rolling along high endothelial venules. Mice deficient in α(1,3) Fucosyltransferase IV and VII (FtDKO) lack functional L, P and E selectin ligands. Thus, we addressed whether the lack of selectin ligand interactions alters tumor protection by CD8+ T cells in FtDKO mice. Listeria monocytogenes-OVA (LM-OVA) infection evoked potent OVA-specific CD8+ T cells that proliferated and contracted at similar kinetics and phenotype in FtDKO and wild-type mice. Additionally, OVA-specific CD8+ T cells in both mouse strains exhibited similar phenotypic differentiation, in vivo cytolytic activity and IFN-γ expression. However, FtDKO mice succumbed to B16-OVA tumors significantly earlier than wild-type mice. In contrast, FtDKO mice evoked strong recall memory CD8+ T cell responses and protection to systemic LM-OVA re-challenge. The diminished tumor protection in FtDKO mice was not related to defective antigen presentation by dendritic cells or reduced proliferation of antigen-specific CD8+ T cells. However, WT or FtDKO OVA-specific CD8+ T cells showed significantly reduced ability to traffic to lymph nodes upon adoptive transfer into naïve FtDKO recipients. Furthermore, FtDKO OVA-specific CD8+ T cells displayed poor ability to infiltrate tumors growing in WT mice. These results reveal that selectin ligand expression on host endothelium as well CD8+ T cells may be important for their efficient and continued extravasation into peripheral tumors.

Highlights

  • Vaccination represents a promising approach towards tumor eradication as CD8+ T cells play an important role in anti-tumor immunity [1]

  • Memory CD8+ T cells can vary in both magnitude and quality [7,8,9] and generating a central memory population with a high level expression of CD62L (TCM) yields longer lasting tumor regression compared to CD62L low effector memory cells (TEM) [10,11,12]

  • We have previously reported that the choice of vaccine adjuvant and/ or vector can differentially impact the proportion of the two types of memory CD8+ T cells; for example Listeria monocytogenes generates a predominant CD62Lhigh central memory cells [13]

Read more

Summary

Introduction

Vaccination represents a promising approach towards tumor eradication as CD8+ T cells play an important role in anti-tumor immunity [1]. Cancer antigen delivered by live bacterial and viral vectors such as recombinant Listeria monocytogenes, Salmonella enterica serovar Typhimurium and adenovirus have been effective at inducing strong CD8+ T cells against immunogenic tumors like metastatic melanoma [2,3,4,5,6]. Adoptive transfer therapies involving tumor-antigen specific CD8+ T cells have shown cancer regression in clinical trials [1]. We have previously reported that the choice of vaccine adjuvant and/ or vector can differentially impact the proportion of the two types of memory CD8+ T cells; for example Listeria monocytogenes generates a predominant CD62Lhigh central memory cells [13]. Clinical trials have revealed only a modest benefit of cancer immunotherapy and new approaches are required for objectively maximizing CD8+ T cell longevity, mobility, functionality and memory responsiveness [1]

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.